DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer
Condition: Breast Cancer
Protocol D967UC00001: Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer
Patients eligible for participation in this study will have advanced and unresectable or metastatic HER2-positive breast cancer that has not yet been treated in the metastatic setting. Participants will be randomized to receive: T-DXd +/- pertuzumab or standard chemotherapy.
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.